Trial Profile

A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEn 1124 (Primary)
Indications Adult respiratory distress syndrome
Focus Adverse reactions
Sponsors GEn1E Lifesciences

Most Recent Events

22 Oct 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
22 Oct 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2026.
21 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com